Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Category: Inequitable Conduct
-
Pfizer Earns One More Victory in Norvasc Litigation By Robert Dailey — This week Pfizer won another courtroom battle against generic drug manufacturer Synthon in the companies' ongoing dispute over Pfizer's drug Norvasc. The District Court held two Synthon patents, U.S. Patent Nos. 6,653,481 and 6,858,738 unenforceable due to inequitable conduct. Pfizer had…
-
By Donald Zuhn — In an appeal from a District Court judgment holding claims 1-5 of U.S. Patent No. 5,527,814 (the '814 patent) enforceable, valid, and infringed, the Federal Circuit affirmed the District Court's finding of no inequitable conduct, vacated the District Court's finding that claims 1-5 of the '814 patent were not invalid…
Patent Docs 